Anticoagulation
Conditions
Keywords
pharmacist-managed anticoagulation, warfarin, acenocoumarol
Brief summary
For decades, vitamin K antagonists are the main oral anticoagulants used for primary and secondary prevention of arterial and venous thromboembolic events. Both observational and randomized controlled trials have confirmed an outstanding outcome (the percentage of time in the therapeutic range-TTR, effectiveness and safety) in patients received anticoagulation management provided by pharmacists (AMPP) in comparing with usual physician care. However, at present, pharmacist-managed anticoagulation services are still not popular in developing countries. In addition, there are few studies evaluating the patient outcomes with the AMPP model in Vietnam. Above all, it is important to explore whether AMPP is superior to other usual models in the improvement of effectiveness and safety.
Detailed description
The study is a randomized controlled trial. Patients who will use VKA are prospectively divided into routine group and pharmacist intervention group. For the intervention group, patients receive an intensive medical education from pharmacists in anticoagulation management service. Pharmacists regularly provide telephone and outpatient follow-up. At the end of the 12-month follow-up, the percentage of TTR and major bleeding events will be evaluated in both groups. Clinical data is designed to be collected from 800 patients, 400 patients in each group. Data will be analyzed by SPSS 20.0 software. P \< 0.05 is considered significant.
Interventions
OTHERPatient education and compliance
When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
Sponsors
University of Medicine and Pharmacy at Ho Chi Minh City
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients received a discharge prescription with VKA therapy from November 2018 * Patients agree to participate in the study * Age 18 and older * Duration of VKA therapy ≥12 months
Exclusion criteria
* Patients with cognitive impairment as diagnosed by physician * Geographical and financial conditions do not allow patients to guarantee follow-up examination on schedule * Patient has less than 3 INR test results after the first day participating in the study * Cannot contact patient by phone call or face-to-face communication after the first day participating in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time in the therapeutic range (TTR) | 12 months | The time in the therapeutic range (TTR) has been used as a measure of warfarin therapy quality. The percentage of TTR is the percentage of the number of patient's INR achieved therapeutic range on the total number of patient's INR test in the 12-month follow-up of each patient. |
| Bleeding events | 12 months | Major bleeding is considered to be those events that resulted in death or the need for acute medical or surgical intervention, also as defined by previously described criteria. Minor bleeding includes increased bruising on the skin and other bleeding episodes not meeting the criteria for major bleeding. |
Countries
Vietnam
Contacts
Primary ContactTien Hoang Tran, BSPharm
Outcome results
None listed